Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02804828
Other study ID # GW140146
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 9, 2021
Est. completion date April 3, 2023

Study information

Verified date April 2023
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop preliminary evidence, such as effect size and variance estimates, to guide successful conduct of a properly-powered clinical trial to assess the benefit of a mitochondrial cocktail (incorporating individualization of treatment) in Gulf War illness (GWI).


Description:

See below.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date April 3, 2023
Est. primary completion date April 3, 2023
Accepts healthy volunteers No
Gender All
Age group 48 Years and older
Eligibility Inclusion Criteria: - Meet symptom criteria for Gulf War illness with BOTH the Centers for Disease Control and Prevention (CDC) Criteria (persistent symptoms in at least 2 of 3 designated symptom domains of fatigue/sleep, mood/cognition, and musculoskeletal) and Kansas Criteria (score a moderate or severe rating in at least 3 of the 6 symptom domains of fatigue, pain, neurological/cognitive/mood, skin, GI and respiratory). Exclusion Criteria: - Have conditions like multiple sclerosis or lupus that can produce similar symptoms and be confused for Gulf War illness. - Participating in a concurrent treatment trial. - Unwilling or unable to comply with the treatment protocol - Failed run-in; do not take at least 80% of run-in medications

Study Design


Intervention

Dietary Supplement:
Individualized mitochondrial cocktail
Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).
Placebo
6 months for the double-blind phase

Locations

Country Name City State
United States UC San Diego La Jolla California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in single item General Self-Rated Health Visual Analog Scale from baseline 0, 3, 6 months (double-blind phase)
Primary Percent improved on Gulf War Illness Modified Lower Extremity Performance Score/timed chair rises 6 months (double-blind phase)
Primary Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. placebo 0, 3, 6 months (double-blind phase)
Primary Mean change of CoQ10 and Vitamin E levels, comparing active treatment to placebo 6 months (double-blind phase)
Secondary Assessment of summed symptom score (sum of ratings for UCSD GWI symptom index) Secondary measures will incorporate assessment of summed symptom score (sum of ratings for UCSD GWI symptom index) at primary endpoint time point. We will assess at additional time points (9, 12 month) and will assess effects stratified by sex; by dominant ethnicity; and by use of medications that can affect levels or disposition of supplement components (e.g. statin use). 6, 9, 12 months
See also
  Status Clinical Trial Phase
Completed NCT00129454 - Telemedicine Treatment for Veterans With Gulf War Illness N/A
Completed NCT00100412 - Hyporeactivity and Gulf War Illness N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Recruiting NCT04987775 - GWICTIC: NAC Mechanistic Study in Gulf War Veterans Early Phase 1
Completed NCT03342482 - Glutamate Neuro-Excitotoxicity in GWI N/A
Completed NCT01264471 - Mechanisms of Mitochondrial Defects in Gulf War Syndrome N/A
Terminated NCT03547869 - Transcranial Direct Current Stimulation for Pain Treatment in Gulf War Illness. N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Recruiting NCT05736146 - Validating Gulf War Illness Blood Biomarkers
Completed NCT03560830 - START & STOPP in GWI
Recruiting NCT05355272 - Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) Phase 2
Terminated NCT04712071 - Ketamine in Veterans With Gulf War Illness Early Phase 1
Completed NCT03030794 - Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS N/A
Completed NCT04638998 - Assessing Neuroinflammation in GWI Using MRS
Recruiting NCT02848417 - Glutathione vs. Curcumin Clinical Trial Phase 1/Phase 2
Recruiting NCT00956150 - Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex Phase 1
Completed NCT00018707 - Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress N/A
Not yet recruiting NCT05992311 - Clinical Evaluation of Montelukast in Veterans With Gulf War Illness Phase 1